anaplastic lymphoma kinase


Also found in: Acronyms.

anaplastic lymphoma kinase

A member of the insulin receptor subfamily of receptor tyrosine kinases, which acquires transforming capability when truncated and fused to nucleophosmin in the t(2;5) chromosomal rearrangement, resulting in the NPM-ALK chimeric protein associated with NHL.

Normal expression
Small intestine, testis, brain.
References in periodicals archive ?
A case of inflammatory myofibroblastic tumor of the urinary bladder finally diagnosed by anaplastic lymphoma kinase (ALK) immunostaining.
cALCL almost never harbors the anaplastic lymphoma kinase translocations that are common to nodal ALCL; accordingly, we did not test for those molecular alterations.
biopharmaceutical business of Merck KGaA, Darmstadt, Germany, today announced it has begun co-promoting Pfizer's anaplastic lymphoma kinase (ALK) inhibitor XALKORI[sup.
In order to prescribe the drug the patient must be positive for anaplastic lymphoma kinase (ALK)-positive genetic rearrangement.
Forces affecting developers, producers and sellers of those pharmaceuticals The report explains issues, events and research and development (R&D) affecting that industry and market from 2014, including these: - Scope of protein kinases in oncology - R&D from 2014 - Cyclin-dependent kinase 4/6 inhibitors in development - Anaplastic lymphoma kinase (alk) compounds in testing - Bruton's tyrosine kinase and PI3K agents for the future - MEK and BRAF inhibition and other mechanisms of action.
Novartis today announced data on its investigational compound LDK378 showing a marked clinical response in 78 patients with anaplastic lymphoma kinase positive (ALK+) metastatic non-small cell lung cancer (NSCLC) who had progressed during or after crizotinib therapy or had not been previously treated with crizotinib.
A specific example of the marker anaplastic lymphoma kinase, originally discovered in anaplastic large cell lymphoma, with expression present and now reported in many tumor types, as shown in Table 2, has generated recent renewed interest as a small-molecule tyrosine kinase inhibitor.
Nasdaq: RGDX), a company focused on the development and sale of molecular diagnostic tests for cancer, today announced the addition of new anaplastic lymphoma kinase (ALK) testing capabilities.
Zykadia is approved to treat anaplastic lymphoma kinase (ALK)-positive metastatic non-small cell lung cancer (NSCLC) in patients who have progressed on or are intolerant to crizotinib.
Novartis announced today that its investigational compound LDK378 has received Breakthrough Therapy designation by the US Food and Drug Administration (FDA) for the treatment of patients with anaplastic lymphoma kinase positive (ALK+) metastatic non-small cell lung cancer (NSCLC) who had progressed during treatment with, or were intolerant to, crizotinib.